Doximity, Inc. Class A (DOCS) Covered Calls

Doximity, Inc. is the leading digital platform for medical professionals in the United States. The company provides a secure, HIPAA-compliant network that enables physicians and clinicians to collaborate, stay current with medical news, and manage patient care. Through its unified suite of digital workflow tools, including telehealth and AI-powered documentation, Doximity helps healthcare professionals improve productivity and deliver more efficient care across the medical ecosystem.

You can sell covered calls on Doximity, Inc. Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DOCS (prices last updated Tue 4:16 PM ET):

Doximity, Inc. Class A (DOCS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
24.07 +0.31 24.00 24.10 2.9M 20 4.4
Covered Calls For Doximity, Inc. Class A (DOCS)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 25 1.00 23.10 4.3% 62.8%
Apr 17 25 1.70 22.40 7.6% 52.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Doximity, Inc. (DOCS) operates the premier professional medical network in the U.S., reaching over 85% of physicians and two-thirds of nurse practitioners and physician assistants. Headquartered in San Francisco, the company provides a comprehensive digital ecosystem designed to streamline the professional lives of healthcare providers. Its business model is primarily subscription-based, with revenue generated from pharmaceutical companies and health systems that utilize the platform for targeted marketing, talent acquisition, and enterprise-level clinical workflow integration.

The platform’s core value lies in its high-utility workflow tools. Doximity Dialer has consistently been ranked as a top telehealth solution, facilitating hundreds of thousands of virtual patient visits daily. In early 2026, the company significantly advanced its technological lead by integrating the Pathway AI corpus into its DocsGPT suite. This allows clinicians to access peer-reviewed, evidence-based answers and automate administrative tasks like drafting clinical appeals or summarizing complex faxes. By early 2026, more than 100 health systems had already purchased enterprise access to these secure AI tools, covering over 180,000 prescribers.

Competitive Landscape

The competitive landscape for Doximity involves a mix of legacy telehealth providers and specialized healthcare technology firms. Primary rivals that are publicly traded on the NYSE or NASDAQ and offer active options markets include Teladoc Health, Inc. and Phreesia, Inc.. These companies compete for dominance in the digital health and patient engagement sectors.

Other notable competitors in the broader medical information and digital services space with active options trading include Veeva Systems Inc. and GoodRx Holdings, Inc.. While LinkedIn serves as a general professional network, Doximity distinguishes itself through its verified, physician-only community and HIPAA-compliant architecture. This specialized focus has allowed the company to maintain high net revenue retention, particularly among its top 20 pharmaceutical clients who utilize the platform’s high-engagement newsfeed to reach medical decision-makers.

Strategic Outlook

Strategic innovation is currently focused on the commercialization of "Agentic AI" to alleviate provider burnout. By early 2026, the company has deployed a new AI Scribe tool that features a 75% weekly retention rate, signaling its success as a "sticky" workflow integrated directly into the point of care. These investments in AI infrastructure are intended to offset slowing growth in legacy digital advertising by opening new revenue streams through enterprise software licenses for health systems looking to standardize their AI-assisted clinical workflows.

The outlook involves a disciplined capital allocation strategy, highlighted by a $500 million share repurchase program authorized in February 2026. Management is prioritizing margin stability, aiming to maintain adjusted EBITDA margins near 55% despite increased spending on AI compute and infrastructure. By leveraging its dominant market share and expanding its self-service portal for smaller agencies, Doximity aims to navigate policy-driven shifts in pharmaceutical marketing budgets while solidifying its role as the essential operating system for the modern U.S. physician.